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Summary
Background: Mortality and morbidity after acute coronary syndrome (ACS) in Japan appear to
be different from those in Western countries due to different social healthcare systems, races,
geographical locations, and interventional procedures, although data are limited in Japan.
Methods: With a hospital-based cohort study comprising all the new patients who had visited our
hospital between 2004 and 2007 (n = 6562), we identiﬁed all-cause mortality, the composite end-
point of cardiac death, non-fatal myocardial infarction (MI), or target vessel revascularization
and the predictors.
Results: Of the total, 293 patients were included with a discharge diagnosis of ACS (median
follow-up of 24.5 months). Non-ST elevation-ACS (NSTE-ACS) (unstable angina and non-ST ele-
vation MI) and ST elevation MI (STEMI) were observed in 165 (56.3%) and 128 (43.7%) patients,
respectively. Percutaneous coronary intervention or coronary artery bypass graft surgery was
performed in 72.7% and 14.5% of NSTE-ACS patients, respectively and in 82.8% and 10.2% of
STEMI patients. The use of aspirin, ticlopidine, and beta-blockers for NSTE-ACS patients were
93.3%, 66.9%, and 38.0%, respectively, with corresponding rates of 96.0%, 75.4%, and 57.1%
for STEMI patients. All-cause mortality rates in NSTE-ACS and STEMI were 1.8% and 5.5% at 30
days, respectively, and 6.3% and 12.9% at 2 years, with corresponding rates of 3.7% and 8.7%
at 30 days, respectively, and 23.4% and 35.6% at 2 years for the composite endpoint. Multivari-
ate analysis showed that predictors for mortality were older age (hazard ratio [HR] 1.13, 95%
conﬁdence interval [CI] 1.018—1.244) and estimated glomerular ﬁltration rate value (HR 0.96,
95% CI 0.929—0.988) in NSTE-ACS, and older age (HR 1.10, 95% CI 1.011—1.119) and congestive
heart failure on admission (HR 20.0, 95% CI 2.439—164.4) in STEMI.
∗ Corresponding author. Tel.: +81 3 3408 2151; fax: +81 3 3401 0469.
E-mail address: nmichi-kyu@umin.ac.jp (M. Nakamura).
0914-5087/$ — see front matter © 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Conclusions: The present study identiﬁed long-term mortality, morbidity, and predictors of
patients with ACS.
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he mortality and morbidity of acute coronary syndrome
ACS) patients have been believed to be different from those
n Western countries because of wide variations between
ountries in ethnicity, geographical locations, social health-
are systems, medications, and invasive cardiac procedures
1—11]. In addition, it should be noted that percutaneous
oronary intervention (PCI) with stenting is more common
or early-stage ACS in Japan, which may lead to different
utcomes in Japanese patients.
Until now, most of the registries in Japan have focused
n highly selected myocardial infarction (MI) patients under-
oing PCI or coronary artery bypass graft surgery (CABG),
recluding information regarding the remaining patients
ith ACS [3—5,8]. ACS, however, includes a variety of clinical
cenarios ranging from unstable angina to non-ST elevation
I to ST elevation MI (STEMI). Few studies have been per-
ormed that investigated long-term mortality and morbidity
fter ACS based on an unselected cohort in Japan. It also
emains uncertain whether previously reported studies can
e generalized to current PCI practice and medications due
o rapidly progressing treatment.
Recently, medical practice for ACS has been strongly
nﬂuenced by large-scale nationwide studies conducted in
estern countries [12—16], and many physicians in Japan
onstruct the treatment strategy by using that clinical
vidence. Therefore, the evidence for contemporaneous
rognosis of Japanese ACS patients should be established.
ccordingly, we have conducted a hospital-based cohort
tudy of the Shinken Database since 2004 to investigate the
revalence and prognosis of patients with cardiovascular dis-
ases in Japan [17]. The purpose of the present study with
his database was to identify the prognosis of ACS patients
nd determine the predictors for all-cause death and the
ardiovascular events.
ethods
rganization and subjects
he study population comprised all the new patients who
ad visited our hospital’s cardiac catheterization labora-
ory and cardiac surgery facility between June 2004 and
arch 2007 and did not meet the exclusion criteria includ-
ng patients with cancer under no treatment, patients living
broad, and patients visiting just one time without any
xaminations.
When written informed consent for entering the Shinken
atabase was obtained from the patient, all data were
ransmitted to the Shinken database center at the hospital,
nd all their clinical outcomes were monitored by med-
cal recordings, mail, and/or telephone contact with the
atients. The ethical committee in the institute granted
thical permission for this study.
T
m
f
Sology. Published by Elsevier Ireland Ltd. All rights reserved.
eﬁnitions
mong the Shinken Database population, all patients
iagnosed as non-ST elevation-ACS (NSTE-ACS) (unstable
ngina and non-ST elevation MI) or STEMI on discharge
ere identiﬁed. STEMI group was deﬁned as patients
ho had at least 20min of ischemic symptoms and had
ew or presumed new ST-segment elevation of at least
.1mV in two limb leads or of 0.2mV in at least two
ontiguous precordial leads or had new left bundle-
ranch block on the admission electrocardiogram with at
east one positive cardiac biochemical marker of necrosis
ncluding troponin I. NSTE-ACS was deﬁned by electro-
ardiographic ST-segment depression or prominent T-wave
nversion and/or troponin I 0.2 ng/ml or more in the
bsence of ST-segment elevation and in an appropriate
linical setting (chest discomfort or angina equivalent)
12,18].
The present study included information on baseline char-
cteristics of patients and their cardiac history, risk factors,
esion characteristics, therapeutic strategies, and medica-
ions. Diabetes mellitus was deﬁned as a history of antidi-
betic therapy or as a combination of glycated hemoglobin
1c≥ 6.5% and either fasting plasma glucose≥ 126mg/dl or
h-plasma glucose≥ 200md/dl. Hypertension was deﬁned
s a history of systolic blood pressure≥ 140mmHg, diastolic
lood pressure≥ 90mmHg, or a history of antihypertensive
herapy. Dyslipidemia was deﬁned as fasting total choles-
erol≥ 220mg/dl, fasting triglycerides≥ 150mg/dl, or a
istory of lipid-lowering therapy. Hyperuricemia was deﬁned
s plasma uric acid > 7.0mg/dl. Angiographically signiﬁcant
tenosis was deﬁned as ≥ 50% stenosis. Congestive heart fail-
re was deﬁned as Killip class II and more. Target vessel
evascularization (TVR) was deﬁned as PCI within a vessel
reated during the index procedure or CABG after the index
rocedure. The composite endpoint was deﬁned as cardiac
eath, non-fatal MI, or TVR.
PCI was a ﬁrst-line treatment for ACS patients in the
resent study, although CABG was performed in case PCI
perators and attending physicians judged PCI as inappro-
riate. In our hospital, early invasive procedures such as PCI
r CABG were performed for patients with not only STEMI
ut also NSTE-ACS. We used troponin I assay as part of a
outine policy when patients with suspected ACS arrived at
ur hospital. The cut-off value for abnormal was deﬁned as
0.2 ng/ml.
ollow-up and data collectionhe following clinical outcomes were evaluated: all-cause
ortality, the composite endpoint of cardiac death, non-
atal MI, or TVR according to the type of ACS: NSTE-ACS and
TEMI.
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Statistical analysis
Continuous variables between groups were compared using
unpaired t-test. Categorical variables were compared using
chi-square test. Results for continuous data were expressed
as mean± standard deviation. Cumulative event curves
were plotted by the Kaplan—Meier method, and the differ-
ence was tested by log-rank test. The association between
the characteristics at the initial visit and the outcomes was
assessed using Cox-proportional-hazard models by a step-
wise procedure, including 4 covariates: age, gender, the
estimated glomerular ﬁltration rate value, and presence or
absence of congestive heart failure on admission for all-
cause death, and 8 covariates: age, gender, the estimated
glomerular ﬁltration rate value, presence or absence of dia-
betes mellitus, number of diseased coronary arteries, pres-
P
S
e
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Table 1 Baseline characteristics.
NSTE-AC
Age (year) 66.1±
Male, n (%) 131 (79.
Body mass index (kg/m2) 24.1±
eGFR (ml/min/1.73m2) 70.2±
History of ischemic heart disease
Prior myocardial infarction, n (%) 31 (18.
Prior CABG, n (%) 3 (1.8
Prior PCI, n (%) 21 (12.
Concomitant diseases
Diabetes mellitus, n (%) 66 (40.
Hypertension, n (%) 112 (67.
Dyslipidemia, n (%) 119 (72.
Hyperuricemia, n (%) 25 (15.
Cigarette smoker, n (%) 93 (57.
Lipid values
Triglyceride (mg/dl) 138.3±
Total-cholesterol (mg/dl) 198.6±
LDL-cholesterol (mg/dl) 113.6±
HDL-cholesterol (mg/dl) 49.3±
Hemoglobin (mg/dl) 13.1±
Killip class
I, n (%) 146 (88.
II, n (%) 13 (7.9
III, n (%) 2 (1.2
IV, n (%) 4 (2.4
Congestive heart failure on admission, n (%) 19 (11.
Number of diseased vessels, n 1.8±
Culprit vessel
Right coronary artery, n (%) 42 (26.
Left anterior descending artery, n (%) 92 (57.
Left circumﬂex coronary artery, n (%) 34 (21.
Left main coronary artery (LMCA), n (%) 13 (8.1
Presence of LMCA disease, n (%) 19 (11.
NSTE-ACS, non-ST elevation acute coronary syndrome; STEMI, ST eleva
rate; CABG, coronary artery bypass graft surgery; PCI, percutaneous
density lipoprotein. Continuous values are expressed as mean± standa
a t-Test for continuous variables; chi-square for categorical variables71
nce or absence of congestive heart failure on admission,
aseline low-density lipoprotein (LDL)-cholesterol value,
nd baseline high-density lipoprotein (HDL)-cholesterol
alue for the composite endpoint. Analyses of data were
erformed using statistical software (SPSS version 14.0; SPSS
apan Inc., Tokyo, Japan). All p-values were 2-sided, and
igniﬁcance was deﬁned as p < 0.05 for all analyses.
esultsatient population and types of ACS
ix thousand ﬁve hundred and sixty-two patients were
nrolled in the Shinken Database 2004-7 and followed up.
f the total, 293 patients presented with ACS at the initial
S n = 165 STEMI n = 128 p valuea
10.1 66.8± 13.7 0.649
4) 107 (83.6) 0.451
2.98 23.8± 3.08 0.549
19.4 65.0± 25.2 0.050
8) 14 (10.9) 0.073
) 2 (1.6) 1.000
7) 7 (5.5) 0.045
0) 41 (32.0) 0.179
9) 72 (56.3) 0.051
1) 78 (60.9) 0.046
2) 20 (15.6) 1.000
1) 74 (57.8) 0.906
85.5 131.1± 120.1 0.560
39.7 192.8± 39.5 0.229
33.4 116.0± 31.8 0.553
14.3 45.4± 12.8 0.021
1.7 12.7± 2.2 0.158
5) 81 (63.3) <0.001
) 21 (16.4) 0.028
) 8 (6.3) 0.023
) 18 (14.1) 0.001
5) 47 (36.7) <0.001
0.9 2.0± 0.9 0.069
3) 42 (33.6) 0.192
5) 62 (49.6) 0.190
3) 25 (20.0) 0.883
) 3 (2.4) 0.041
8) 12 (9.6) 0.573
tion myocardial infarction; eGFR, estimated glomerular ﬁltration
coronary intervention; LDL, low-density lipoprotein; HDL, high-
rd deviation.
.
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isits (4.5%). NSTE-ACS and STEMI were observed in 165
56.3%) and 128 (43.7%) patients, respectively. The median
ollow-up period of patients with ACS was 24.5 months.
atient characteristics
able 1 shows the baseline clinical characteristics and angio-
raphic ﬁndings according to the discharge diagnosis of
STE-ACS and STEMI. The mean age, body mass index, esti-
ated glomerular ﬁltration rate, and the proportion of male
ender were similar between NSTE-ACS and STEMI patients.
he frequency of concomitant diseases was also similar
mong the 2 groups except for dyslipidemia, while more
atients with STEMI had congestive heart failure on admis-
ion (36.7% in STEMI and 11.5% in NSTE-ACS) (p < 0.001).
he baseline lipid values and hemoglobin value were similar
etween NSTE-ACS and STEMI patients, with the exception
f HDL-cholesterol value [49.3± 14.3mg/dl in NSTE-ACS and
5.4± 12.8mg/dl in STEMI patients (p = 0.021)]. There was
o signiﬁcant difference in culprit vessel between NSTE-ACS
nd STEMI except for left main coronary artery, and the rate
mong culprit vessels in the present study was similar to
hat in other surveys. The number of diseased vessels was
.8± 0.9 in NSTE-ACS and 2.0± 0.9 in STEMI, respectively
p = 0.069).
r
u
c
(
Table 2 Treatment for acute coronary syndrome.
Variables N
First strategy and procedure of revascularization
Medical, n (%)
CABG, n (%)
PCI, n (%) 1
Stent, n (%) 1
Bare-metal stents, n (%)
Drug-eluting stents, n (%)
Directional coronary atherectomy, n (%)
PTCRA, n (%)
Thrombus aspiration, n (%)
Distal protection, n (%)
Use of Intravascular ultrasound, n (%) 1
Need of intra-aortic balloon pumping, n (%)
Need of percutaneous cardiopulmonary support, n (%)
Medication at discharge
Angiotensin-converting enzyme inhibitor, n (%)
Angiotensin receptor blocker, n (%)
Beta-blocker, n (%)
Statin, n (%)
Ca channel blocker, n (%)
Aspirin, n (%) 1
Cilostazol, n (%)
Ticlopidine, n (%) 1
Nitrate, n (%)
Nicorandil, n (%)
PTCRA, percutaneous transluminal coronary rotational atherectomy. A
a t-Test for continuous variables; chi-square for categorical variablesM. Nakamura et al.
rocedural characteristics and medications at
ischarge
mong patients with NSTE-ACS, 87.2% received invasive
trategies: 72.7% of primary PCI and 14.5% of CABG. Mean-
hile, among patients with STEMI, 93.0% received invasive
reatments: 82.8% of primary PCI and 10.2% of CABG. These
ates were quite high compared with registries conducted to
ate (20—55%) [9—11]. Bare-metal stents were implanted in
6.1% of NSTE-ACS and 75.8% of STEMI (p < 0.001), whereas
rug-eluting stents were implanted in 41.8% of NSTE-ACS
ut patients with STEMI did not receive drug-eluting stents
ue to our hospital policy (p < 0.001). The rates of stent use
ere similar to those of the JMIC-D [2]. Therefore, the PCI
rocedure for ACS in our hospital was thought to be sim-
lar to other hospitals in Japan. Thrombus aspiration and
istal protection were performed in 11.5% and 8.5% of NSTE-
CS patients, respectively and in 53.9% and 21.9% of STEMI
atients, respectively. Angiotensin-converting enzyme (ACE)
nhibitor and beta-blocker were received by more patients
ith STEMI; in contrast, Ca channel blocker and nitrate were
eceived by more patients with NSTE-ACS (Table 2).
The overall angiographic success rate, deﬁned as a resid-
al stenosis of ≤25% and anterograde reperfusion of the
ulprit vessel with Thrombolysis In Myocardial Infarction
TIMI) grade 3 ﬂow, was 98.6% of patients treated with PCI.
STE-ACS n = 165 STEMI n = 128 p valuea
21 (12.7) 9 (7.0) 0.124
24 (14.5) 13 (10.2) 0.291
20 (72.7) 106 (82.8) 0.050
10 (66.7) 97 (75.8) 0.094
43 (26.1) 97 (75.8) <0.001
69 (41.8) 0 (0.0) <0.001
15 (9.1) 2 (1.6) 0.005
5 (3.0) 3 (2.3) 1.000
19 (11.5) 69 (53.9) <0.001
14 (8.5) 28 (21.9) 0.004
15 (69.7) 98 (76.6) 0.234
18 (10.9) 22 (17.2) 0.127
0(0) 3 (2.3) 0.082
21 (12.9) 49 (38.9) <0.001
51 (31.3) 39 (31.0) 1.000
62 (38.0) 72 (57.1) 0.001
89 (54.6) 61 (48.4) 0.342
86 (52.8) 22 (17.5) <0.001
52 (93.3) 121 (96.0) 0.438
9 (5.5) 5 (4.0) 0.593
09 (66.9) 95 (75.4) 0.120
45 (27.6) 10 (7.9) <0.001
75 (46.0) 48 (38.1) 0.189
bbreviations as in Table 1.
.
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Table 3 Clinical outcome.
Overall NSTE-ACS STEMI p valuea
All-cause death, n (%) 10 (6.1) 16 (12.5) 0.064
The composite events, n (%) 35 (21.2) 41 (32.0) 0.044
Cardiac death, n (%) 3 (1.8) 11 (8.6) 0.011
Non-fatal MI, n (%) 1 (0.6) 3 (2.3) 0.322
Target vessel revascularization, n (%) 32 (19.4) 32 (25.0) 0.258
(2.4)
i
l
c
c
m
0
(
h
p
pReadmission for heart failure, n (%) 4
Abbreviations as in Table 1.
a Chi-square for categorical variables.
Clinical outcomes
Overall, all-cause death occurred in 10 patients with NSTE-
ACS and 16 patients with STEMI, respectively, and 35 and
41 composite endpoints occurred in patients with NSTE-ACS
and STEMI, respectively (Table 3). The all-cause mortal-
ity rates in NSTE-ACS and STEMI were 1.8% and 5.5% at
30 days, respectively, and 6.3% and 12.9% at 2 years. The
incidences of composite endpoint of cardiac death, non-
fatal MI or, TVR in NSTE-ACS and STEMI were 3.7% and
8.7% at 30 days, respectively, and 23.4% and 35.6% at
2 years (Fig. 1). The all-cause death and the compos-
ite events were more frequently observed within the ﬁrst
1 year after suffering ACS in both NSTE-ACS and STEMI.
After the ﬁrst 1.5 years, the cardiovascular events were
1
h
p
1
Figure 1 (A) Kaplan—Meier curves for survival after initial presen
elevation-ACS (NSTE-ACS) and ST elevation myocardial infarction (ST
(p = 0.046). (B) The composite endpoint-free curves after initial pres
a signiﬁcant difference between the 2 groups (p = 0.018).7 (5.5) 0.220
nfrequent and the event curves of the 2 groups were paral-
el.
Multivariate analysis showed that the predictors for all-
ause death were older age (hazard ratio [HR] 1.13, 95%
onﬁdence interval [CI] 1.018—1.244, p = 0.020) and esti-
ated glomerular ﬁltration rate value (HR 0.96, 95% CI
.929—0.988, p = 0.006) in NSTE-ACS patients, and older age
HR 1.10, 95% CI 1.011—1.119, p = 0.016) and congestive
eart failure on admission (HR 20.0, 95% CI 2.439—164.4,
= 0.005) in STEMI patients. The risk factors for the com-
osite endpoint were diabetes mellitus (HR 2.40, 95% CI
.096—5.259, p = 0.029) in STEMI patients, and congestive
eart failure on admission (HR 3.20, 95% CI 1.110—9.126,
= 0.031) and LDL-cholesterol value (HR 1.01, 95% CI
.000—1.021, p = 0.049) in NSTE-ACS patients.
tation for acute coronary syndrome (ACS) according to non-ST
EMI). There was a signiﬁcant difference between the 2 groups
entation for ACS according to NSTE-ACS and STEMI. There was
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iscussion
he present study comprises an observational cohort of ACS
atients, who were treated with invasive procedures at
uite high rates (around 90%), and revealed the mortality
nd morbidity after ACS. The number of NSTE-ACS patients
reated was 1.29-fold larger than that of STEMI patients.
ll-cause mortality rates in NSTE-ACS and STEMI were 1.8%
nd 5.5% at 30 days, respectively, and 6.3% and 12.9% at
years, with corresponding rates of 3.7% and 8.7% at 30
ays, respectively, and 23.4% and 35.6% at 2 years for the
omposite endpoint.
In the GRACE study, 32% of ACS patients received a ﬁnal
iagnosis of STEMI [11], and the Euro Heart Survey showed
hat the initial diagnosis of ST elevation-ACS was observed
n 42.3% [9]. Meanwhile, in Japan, STEMI was observed in
7.5% of ACS patients according to JMIC-D study [2], which
as similar to that in the present study (43.7%). The reason
hy the proportion of STEMI is higher in Japan than in West-
rn countries is unclear, and further studies to assess the
ifferences in presentation among countries is required.
According to the studies conducted to date in Japan, only
—4% of acute MI patients and 7% with unstable angina had
igniﬁcant stenosis in the left main coronary artery [2,8].
onversely, in the present study, 9.6% of STEMI patients
nd 11.8% with NSTE-ACS had signiﬁcant stenosis in the left
ain coronary artery. Furthermore, in patients with STEMI,
illip classes III and IV were 6.3% and 14.1%, respectively,
hich were high rates compared to other surveys. It may
esult mainly from the fact that some patients with ACS
ere transferred to our hospital due to complex coronary
rtery diseases such as left main coronary artery bifurca-
ion diseases and/or multivessel severely calciﬁed diseases.
espite these worse backgrounds in the present study, the
linical outcomes for STEMI and NSTE-ACS patients treated
ith early invasive strategies at a high rate seem to be sat-
sfactory compared to other registries such as the GRACE,
uroheart ACS, and ENACT surveys.
The use of invasive treatments for ACS is much higher
n Japan (around 90%) compared to Western countries
40—50%) [2,9—11]. In the present study, PCI or CABG was
erformed at a high rate: 72.7% and 14.5% in NSTE-ACS,
espectively and 82.8% and 10.2% in STEMI. With regard to
edications, Euro Heart Survey and GRACE reported that
eta-blockers were administered to both ST elevation and
on-ST elevation-ACS patients in around 70%. In contrast, in
his study patients with STEMI and NSTE-ACS received beta-
locker in 57.1% and 38.0% of cases, respectively, suggesting
hat vasospastic angina is more common in Japan, especially
fter MI and attending physicians might prescribe beta-
lockers only for patients who were expected to develop
eft ventricular remodeling [19]. Meanwhile, some studies
howed that beta-blockers improved survival in Japanese
atients after MI regardless of high frequency of vasospastic
ngina [20,21]. Furthermore, ACE inhibitor or angiotensin
eceptor blocker (ARB) was taken in about 40% of NSTE-ACS
atients and 70% of STEMI patients, whereas statin treat-
ent was received in around 50% in the present study. These
edications are believed to reduce mortality after ACS or
eart failure, although the proportions of patients receiv-
ng these medications were still low in the present study.
t
t
s
tM. Nakamura et al.
herefore, the inﬂuence of low rates of beta-blocker, ACE
nhibitor or ARB, and statins in the present study on the
ong-term prognosis (more than 5 years) remains uncertain
nd other Japanese studies are needed to compare the dif-
erences in prognosis among the studies and to assess the
ffect of medications on prognosis.
Earlier studies conducted in Western countries indicated
hat the 30-day mortality rates were 3.5% for NSTE-ACS and
.4% for ST elevation-ACS, and in-hospital mortality rates
ere 1—2% for unstable angina and 6—8% for MI [9—11].
lso, 1-year predicted mortality rates in STEMI, NSTEMI, and
nstable angina were 19%, 18%, and 10%, respectively, with
orresponding rates of 23%, 16%, and 20% at 3 years [22]. In
he JMIC-D survey, the incidence of cardiac events (death,
I, or urgent revascularization) in unstable angina and
cute MI were 2.0% (cardiac death 1.0%) and 8.0% (cardiac
eath 6.2%), respectively at 30 days [2]. Meanwhile, in this
tudy, all-cause mortality rates in NSTE-ACS and STEMI were
.8% and 5.5% at 30 days, respectively, and 6.3% and 12.9%
t 2 years, with corresponding rates of 3.7% and 8.7% at
0 days, respectively, and 23.4% and 35.6% at 2 years for
he composite endpoint of cardiac death, non-fatal MI, or
VR, suggesting that the mortality rate appears to be lower
n Japan compared with Western countries after suffering
CS. There are some probable explanations. First, several
rials indicated that an early invasive strategy for ACS
NSTE-ACS) had improved long-term survival and reduced
he incidence of adverse events and readmission compared
ith a conservative strategy, especially in high-risk patients
23—27]. PCI for ACS at an early stage is more frequent in
apan than in Western countries and these differences in
trategies for ACS might inﬂuence the prognosis. Although
arly invasive therapy for NSTE-ACS seems to remain a
atter of debate, our study indicated that early invasive
reatment for NSTE-ACS appeared to be safe with favorable
linical outcomes in the real world.
Second, we compared our results with other studies
hich had been conducted in Western countries in the
arlier reperfusion era before 2002 in terms of the prog-
osis, although the GRACE investigators reported that
n-hospital mortality rate signiﬁcantly decreased from
999 to 2005 and was associated with improvement in
he management of ACS patients: 8.4% in 1999 and 4.6%
n 2005 for in-hospital mortality of STEMI patients, and
.9% in 1999 and 2.2% in 2005 for in-hospital mortality of
STE-ACS patients [28]. Accordingly, we should note that
t is possible that the improvement in current management
f ACS patients might inﬂuence the differences in prognosis
mong the studies. Third, routine follow-up examinations
fter ACS such as stress test for evaluating myocardial
schemia or coronary angiography is more common in Japan
han Western countries and they may prevent fatal events
nstead of increasing revascularization rate [29].
One and a half years after ACS onset, the event curves
ere almost parallel and the slopes reached a plateau
egardless of ACS type. However, some of patients with MI
ay develop left ventricular remodeling and cardiac func-ion will decrease with time in those patients. Therefore,
he long-term follow-up of more than 5—10 years after MI
hould be required to evaluate the inﬂuence of MI on mor-
ality in the chronic phase.
[[
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[Mortality and morbidity after ACS
In multivariate Cox-proportional-hazard analysis, older
age and congestive heart failure on admission were inde-
pendently associated with all-cause death in STEMI patients,
and older age and decreased estimated glomerular ﬁltration
rate value in NSTE-ACS patients. The predictors for the com-
posite endpoint were diabetes mellitus in STEMI patients,
and congestive heart failure on admission and higher LDL-
cholesterol value in NSTE-ACS patients. Although predictors
were similar to ﬁndings of prior studies, the present study
revealed that there were differences in the risk factors
for mortality or morbidity between STEMI and NSTE-ACS
patients, suggesting that we should manage ACS patients
in consideration of their risk factors according to the initial
presentation of NSTE-ACS or STEMI.
Study limitations
The present study has several limitations. First, this study
was based on single center experience, and the number
of study patients was small. Accordingly, more studies
with enlarged population size and frequent use of invasive
procedures are required. However, a single center study
permitted the level and strategy of PCI procedures to
be constant, that is, PCI procedures were practiced by
experienced operators, and PCI data were collected by
professional staff and contained detailed clinical and angio-
graphic data. Second, our hospital is a teaching facility;
the results of this study may therefore not be generalized
to all medical centers. Finally, patients with ACS who died
before reaching hospital were not included. Nonetheless,
we believe that the ﬁndings of the present study represent
precise prognosis and predictors after ACS according to
the types of ACS and will provide valuable direction about
the future treatment for Japanese ACS patients, since we
performed this study using a highly accurate method for
diagnosing and following all cardiovascular events.
In conclusion, the present study of an observational
cohort in Japanese ACS patients, revealed long-term mor-
tality, morbidity, and risk factors after NSTE-ACS and STEMI.
Acknowledgments
We would like to thank Drs Ryuichi Funada, Shunsuke
Matsuno, Toshiro Inaba, and Yuya Nakagawa of the Cardio-
vascular Institute for their collection of data. We would also
like to thank all study participants, physicians, co-medical
staff, and co-workers.
References
[1] Yusuf S, Flather M, Pogue J, Hunt D, Varigos J, Piegas L,
Avezum A, Anderson J, Keltai M, Budaj A, Fox K, Ceremuzynski
L. Variations between countries in invasive cardiac proce-
dures and outcomes in patients with suspected unstable angina
or myocardial infarction without initial ST elevation. OASIS
(Organisation to Assess Strategies for Ischaemic Syndromes)
Registry Investigators. Lancet 1998;352:507—14.[2] Yui Y, Hirayama A, Nonogi H, Kimura K, Kodama K, Hosoda S,
Kawai C. Unstable angina and non-ST elevation acute coronary
syndrome-epidemiology and current management in Japan
(Japan Multicenter Investigation for Cardiovascular Disease-D
(JMIC-D) Committee). Circ J 2007;71:1335—47.75
[3] Nishigaki K, Yamazaki T, Fukunishi M, Tanihata S, Fuji-
wara H, Japanese Coronary Intervention Study (JCIS) Group.
Assessment of acute myocardial infarction in Japan by the
Japanese Coronary Intervention Study (JCIS) Group. Circ J
2004;68:515—9.
[4] Nishigaki K, Yamazaki T, Fujiwara H, Japanese Coronary
Intervention Study (JCIS) Group. Assessment of coronary inter-
vention in Japan from the Japanese Coronary Intervention
Study (JCIS) Group-Comparison between 1997 and 2000. Circ
J 2004;68:181—5.
[5] Matsui K, Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki
S, Yamagishi M, Tei C, Hiraoka H, Sonoda M, Tsuchihashi K,
Ooie T, Honda T, Ogata Y, Ogawa H. Japanese Acute Coro-
nary Syndrome Study (JACSS) Investigators. Weekend onset of
acute myocardial infarction does not have a negative impact
on outcome in Japan. Circ J 2007;71:1841—4.
[6] Roe MT, Chen AY, Mehta RH, Li Y, Brindis RG, Smith Jr SC,
Rumsfeld JS, Gibler WB, Ohman EM, Peterson ED. Inﬂuence
of inpatient service specialty on care processes and outcomes
for patients with non ST-segment elevation acute coronary syn-
dromes. Circulation 2007;116:1153—61.
[7] Fox KA, Anderson Jr FA, Dabbous OH, Steg PG, López-Sendón
J, Van de Werf F, Budaj A, Gurﬁnkel EP, Goodman SG, Brieger
D, GRACE Investigators. Intervention in acute coronary syn-
dromes: do patients undergo intervention on the basis of their
risk characteristics? The Global Registry of Acute Coronary
Events (GRACE). Heart 2007;93:177—82.
[8] Shihara M, Tsutsui H, Tsuchihashi M, Tada H, Kono S, Takeshita
A, Japanese Coronary Invention Study (JCIS) Group. In-hospital
and one-year outcomes for patients undergoing percutaneous
coronary intervention for acute myocardial infarction. Am J
Cardiol 2002;90:932—6.
[9] Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma
E, Fioretti PM, Simoons ML, Battler A. A prospective sur-
vey of the characteristics, treatments and outcomes of
patients with acute coronary syndromes in Europe and the
Mediterranean basin-the Euro Heart Survey of Acute Coro-
nary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:
1190—201.
10] Fox KA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg
G on behalf of the ENACT (European Network for Acute
Coronary Treatment) investigators. The ENACT study: a pan-
European survey of acute coronary syndromes. Eur Heart J
21;2000:1440—9.
11] GRACE Investigators. Management of acute coronary syn-
dromes. Variations in practice and outcome; ﬁndings from the
Global Registry of Acute Coronary Events (GRACE). Eur Heart J
2002;23:1177—89.
12] Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM,
Casey Jr DE, Chavey II WE, Fesmire FM, Hochman JS, Levin TN,
Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, et
al. ACC/AHA 2007 guidelines for the management of patients
with unstable angina/non ST-elevation myocardial infarction: a
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Com-
mittee to Revise the 2002 Guidelines for the Management of
Patients With Unstable Angina/Non ST-Elevation Myocardial
Infarction). Circulation 2007;116:e148—304.
13] Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD,
Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN,
Pepine CJ, Schaeffer JW, Smith III EE, Steward DE, Ther-
oux P, et al. American Heart Association. Committee on
the Management of Patients With Unstable Angina. ACC/AHA
2002 guideline update for the management of patients with
unstable angina and non-ST-segment elevation myocardial
infarction—–summary article: a report of the American Col-
lege of Cardiology/American Heart Association task force
on practice guidelines (Committee on the Management of
7[
[
[
[
[
[
[
[
[
[
[
[
[
[
[6
Patients With Unstable Angina). J Am Coll Cardiol 2002;40:
1366—74.
14] Task Force for Diagnosis and Treatment of Non-ST-Segment
Elevation Acute Coronary Syndromes of European Society of
CardiologyBassand JP, Hamm CW, Ardissino D, Boersma E, Budaj
A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin
L, Wijns W. Guidelines for the diagnosis and treatment of non-
ST-segment elevation acute coronary syndromes. Eur Heart J
2007;28:1598—660.
15] Takano T, Ogawa S, Kasanuki H, Kimura K, Goto Y, Sumiyoshi
T, Daida H, Tanaka K, Nagao K, Hirayama A, Makuuchi H, Yam-
aguchi T, Yamashina A, Yoshino H, Asano R, et al. Guidelines
for the management of patients with ST-elevation myocar-
dial infarction (JCS 2008). Circ J 2008;72(Suppl. IV):1347—442
(Japanese).
16] Yamaguchi T, Isshiki T, Ino T, Ogawa H, Kimura T, Sumiyoshi
T, Takano T, Chino M, Tsutsui H, Nakamura M, Nonogi H,
Hirayama H, Makuuchi H, Mitsudo K, Motomiya T, et al. Guide-
lines for management of acute coronary syndrome without
persistent ST segment elevation (JCS 2007). http://www.j-
circ.or.jp/guideline/pdf/JCS2007 yamaguchi h.pdf (accessed
24 August 2009) (Japanese).
17] Nakamura M, Yamashita T, Yajima J, Oikawa Y, Ogasawara K,
Kirigaya H, Sagara K, Koike A, Sawada H, Aizawa T., Impact
of reduced renal function on prognosis in Japanese patients
with coronary artery disease: a prospective cohort of Shinken
Database 2007. Hypertens Res, 2009 Aug 21. [Epub ahead of
print].
18] Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM,
Fihn SD, Foody JM, Kosiborod MN, Masoudi FA, Nallamothu
BK, et al., American College of Cardiology/American Heart
Association Task Force on Performance Measures; Ameri-
can Academy of Family Physicians; American College of
Emergency Physicians; American Association of Cardiovascu-
lar and Pulmonary Rehabilitation; Society for Cardiovascular
Angiography and Interventions. ACC/AHA 2008 performance
measures for adults with ST-elevation and non-ST-elevation
myocardial infarction: a report of the American College
of Cardiology/American Heart Association Task Force on
Performance Measures (Writing Committee to develop per-
formance measures for ST-elevation and non-ST-elevation
myocardial infarction): developed in collaboration with the
American Academy of Family Physicians and the American
College of Emergency Physicians: endorsed by the American
Association of Cardiovascular and Pulmonary Rehabilitation,
Society for Cardiovascular Angiography and Interventions,
and Society of Hospital Medicine. Circulation 2008;118:2596—
648.
19] Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M,
Mongiardo R, Cianﬂone D, Sanna T, Sasayama S, Maseri A. Major
[M. Nakamura et al.
racial differences in coronary constrictor response between
Japanese and Caucasians with recent myocardial infarction.
Circulation 2000;101:1102—8.
20] Yamada K, Tsuji H, Tokunaga S, Kurimoto K, Maeba H, Matsuhisa
S, Inami N, Iwasaka T. Effect of beta-blockers on the mortality
of Japanese patients with myocardial infarction. Int J Cardiol
2006;108:309—13.
21] Shirotani M, Yokota R, Kouchi I, Hirai T, Uemori N, Haba K, Hat-
tori R. Inﬂuence of atenolol on coronary artery spasm after
acute myocardial infarction in a Japanese population. Int J
Cardiol 2008;(November) [Epub ahead of print].
22] Tang EW, Wong CK, Herbison P. Global Registry of Acute Coro-
nary Events (GRACE) hospital discharge risk score accurately
predicts long-term mortality post acute coronary syndrome.
Am Heart J 2007;153:29—35.
23] Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E, Wallentin
L. Fast Revascularisation during InStability in Coronary artery
disease (FRISC-II) Investigators. 5-year outcomes in the FRISC-II
randomized trial of an invasive versus a non-invasive strategy in
non-ST-elevation acute coronary syndrome: a follow-up study.
Lancet 2006;368:998—1004.
24] Choudhry NK, Singh JM, Barolet A, Tomlinson GA, Detsky
AS. How should patients with unstable angina and non-
ST-segment elevation myocardial infarction be managed? A
meta-analysis of randomized trials. Am J Med 2005;118:
465—74.
25] Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Beneﬁt
of early invasive therapy in acute coronary syndromes: a meta-
analysis of contemporary randomized clinical trials. J Am Coll
Cardiol 2006;48:1319—25.
26] Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon
DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A,
Rupprecht HJ, Zhu J, Col J, Natarajan MK, et al. Early versus
delayed invasive intervention in acute coronary syndromes. N
Engl J Med 2009;360:2165—75.
27] O’Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton
TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy
SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Saba-
tine MS. Early invasive vs conservative treatment strategies in
women and men with unstable angina and non-ST-segment ele-
vation myocardial infarction. A meta-analysis. JAMA 2008;300:
71—80.
28] Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson Jr FA,
Granger CB, Flather MD, Budaj A, Quill A, Gore JM, GRACE
Investigators. Decline in rates of death and heart failure
in acute coronary syndromes, 1999—2006. JAMA 2007;297:
1892—900.
29] Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare
metal stent restenosis is not a benign clinical entity. Am Heart
J 2006;151:1260—4.
